3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
12
Prostatic Neoplasms
11
Fallopian Tube Neoplasms
10
Pancreatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
7
Glioblastoma
6
Neoplasm Metastasis
5
Carcinoma, Ovarian Epithelial
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Glioma
4
Small Cell Lung Carcinoma
3
Mesothelioma
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Interventions
Gemcitabine
11
Albumin-Bound Paclitaxel
7
Taxes
5
130-nm albumin-bound paclitaxel
4
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Fluorouracil
3
dehydroftorafur
2
Oxaliplatin
2
Losartan
2
Leucovorin
2
Irinotecan
2
Cisplatin
2
niraparib
1
irinotecan sucrosofate
1
folfirinox
1
durvalumab
1
X-Rays
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Radiosurgery
1
Radiation
1
Panitumumab
1
Pancreaticoduodenectomy
1
Optical Imaging
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Adenocarcinoma
×
niraparib
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts